Bempegaldesleukin (NKTR-214), a CD122 preferential IL-2 pathway agonist, augments the in situ vaccine response to radiation of an extracranial tumor in a murine melanoma model, conferring response at non-radiated tumor sites in the brain-MedSci.cn

Bempegaldesleukin (NKTR-214), a CD122 preferential IL-2 pathway agonist, augments the in situ vaccine response to radiation of an extracranial tumor in a murine melanoma model, conferring response at non-radiated tumor sites in the brain

Clark, PA; Sriramaneni, RN; Pieper, A; Bates, AM; Anderson, BR; Jin, W; Jagodinsky, JC; Rakhmilevich, AL; Morris, ZS

CANCER RESEARCH, 2020; 80 (16):

科室
- - 订阅+
  - 更多科室
工具
服务